Legal & Regulatory Affairs Committee
Following the positive qualification opinion issued by EMA on the EBMT registry in February 2019, EBMT has been engaged in a similar process with EUnetHTA, the EU Joint Action on health technology assessment. The process aims to establish whether the registry is suitable to support HTA purposes in the area of cellular therapies. The pandemic has unfortunately caused delays to the process but we hope to resume progress over the coming weeks